Defects in the p53 pathway have been suggested as determining factors for the sensitivity of 5-FU-based chemotherapy, in several cancer types12,14,15, because p53 status is strongly associated with apoptosis and tumor-suppressing effects. Here, TP53 is linked to neoplasm.